Leukemia | Topics

 
Study Confirms Long-Term Safety, Efficacy of Oral Arsenic Trioxide in Patients with APL
July 11, 2020

Researchers suggested that the use of the oral agent over a prolonged period of time should now be considered part of the overall treatment plan in acute promyelocytic leukemia.

Stephen Schuster, MD, Gives Advice for Treating Aggressive Lymphomas During COVID-19 Pandemic
May 28, 2020

Stephen Schuster, MD, talked about the benefits of conducting routine visits remotely during the COVID-19 pandemic, allowing doctors to see and treat more patients safely and efficiently.

Stephen Schuster, MD, on Prioritizing Patients with Aggressive Lymphomas During COVID-19 Pandemic
May 25, 2020

Stephen Schuster, MD, discussed how they are prioritizing patients with more aggressive lymphomas, with emphasis on tumor volume and serum LDH levels during the COVID-19 pandemic.

Christopher R. Flowers, MD, on Disparities in Lymphoma and Myeloma
May 21, 2020

The lymphoma and myeloma expert indicated that one of the key ways to address these disparities in lymphoma and myeloma is to improve minority and rural accrual in clinical trials.

Expert Discusses Home Treatment for Aggressive Lymphomas Amidst COVID-19 Pandemic
May 20, 2020

Stephen Schuster, MD, explained how Penn Medicine is utilizing at-home treatments, which will continue after the pandemic, to maximize safety and reduce hospital traffic during the COVID-19 pandemic.

Stephen Schuster, MD, Talks Adjustments for Treating Patients with Aggressive Lymphomas During COVID-19 Pandemic
May 14, 2020

Stephen Schuster, MD, of Penn Medicine discussed testing for COVID-19, telemedicine and how they are adjusting their treatment of patients with aggressive lymphomas during the pandemic.

76-Year-Old Woman With a Bluish-Purple Lump in her Left Upper Medial Leg
May 13, 2020

Test your diagnostic knowledge with this month's Image IQ.

Strategies Combining Nivolumab Show Promise for Classic Hodgkin Lymphoma
May 11, 2020

Researchers found that 2 studied strategies, which combined nivolumab and doxorubicin, vinblastine, and dacarbazine, are feasible, highly effective, and result in excellent 12-month progression-free survival.

Continued Treatment with SGX301 in Patients with CTCL Increases Response Rates
May 10, 2020

SGX301 is being evaluated for the treatment of patients with early-stage cutaneous T-cell lymphoma in the pivotal phase III FLASH study, which demonstrated that continued treatment twice weekly for 12 weeks increased the positive response rate.

DETECT-A Blood Test Combined with PET-CT May Lead to Surgery with Intent to Cure
May 08, 2020

In this study, the feasibility and safety of DETECT-A coupled with PET-CT imaging to detect cancer was evaluated using a prospective, interventional study of 10,006 women not previously known to have cancer.